Chitosan Nanoparticles for Intranasal Drug Delivery

• Published in: Pharmaceutics Vol. 16; no. 6; p. 746
• Main Authors: Omidian, Hossein, Gill, Erma J, Dey Chowdhury, Sumana, Cubeddu, Luigi X
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.06.2024; MDPI
• Subjects: Bioavailability; Brain research; Chemical properties; Chitin; chitosan nanoparticles; clinical translation; Composite materials; Disease; Dopamine; Dosage and administration; Drug delivery systems; Drugs; Efficiency; Evaluation; intranasal drug delivery; Microscopy; Nanoparticles; Nervous system; neurodegenerative disorders; Permeability; Physiology; Protective coatings; regulatory challenges; Review; Vehicles; United States; regulatory challenges; chitosan nanoparticles; clinical translation; intranasal drug delivery; neurodegenerative disorders
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics16060746

This manuscript explores the use of nanostructured chitosan for intranasal drug delivery, targeting improved therapeutic outcomes in neurodegenerative diseases, psychiatric care, pain management, vaccination, and diabetes treatment. Chitosan nanoparticles are shown to enhance brain delivery, improve bioavailability, and minimize systemic side effects by facilitating drug transport across the blood-brain barrier. Despite substantial advancements in targeted delivery and vaccine efficacy, challenges remain in scalability, regulatory approval, and transitioning from preclinical studies to clinical applications. The future of chitosan-based nanomedicines hinges on advancing clinical trials, fostering interdisciplinary collaboration, and innovating in nanoparticle design to overcome these hurdles and realize their therapeutic potential.